News for ClearPoint Neuro, Inc. (CLPT)

U.S. stocks were lower, with the Dow Jones index falling around 550 points on Thursday. Shares of uniQure N.V. QURE rose sharply during Thursday's session afte...

ClearPoint's Q4 updates: neurosurgery growth, expanding services, controlled cash burn and high-potential partner programs driving future prospects. See more here.

Total Revenue (2024): $31.4 million, a 31% increase from $24 million in 2023.Biologics and Drug Delivery Revenue (2024): $17.3 million, up 27% from $13.6 milli

Achieved Record Revenue for 2024 and Growth of 31%;Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / Cl

ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -33.33% and 10.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Quarterly Revenue: $7.8 million, slightly below the estimated $8.23 million, marking a 14% increase year-over-year.Annual Revenue: Achieved $31.4 million, slig

ClearPoint Neuro Inc (CLPT) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue is $8.23 million, and the earning

SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling

SOLANA BEACH, CA / ACCESS Newswire / February 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling

ClearPoint Neuro (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CLPT Stock Touches 52-Week High at $17.49 Amidst Strong Yearly Growth

ClearPoint Neuro (CLPT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Shares of ClearPoint Neuro Inc (CLPT) fell 4.13% in mid-day trading on Dec 27. The stock reached an intraday low of $15.70, before recovering slightly to $15.

CLPT Stock Touches 52-Week High at $14.22 Amidst Strong Growth

Shares of ClearPoint Neuro Inc (CLPT) surged 4.29% in mid-day trading on Nov 29. The stock reached an intraday high of $12.63, up from its previous close of $

The U.S. Food and Drug Administration approved PTC Therapeutics, Inc.'s Kebilidi (eladocagene exuparvovec-tneq) gene therapy for the treatment of aromatic L-amino acid decarboxylase or AADC deficiency.

ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively. Check out my recommendation for CLPT stock.

Total Revenue: $8.1 million for Q3 2024, up 41% from $5.8 million in Q3 2023.Biologics and Drug Delivery Revenue: $4.4 million, a 27% increase from $3.5 millio

Nov 07, 2024 / 09:30PM GMTOperator Greetings and welcome to the Clearpoint Neuro Inc third quarter 2024 financial results conference call at this time. All part